Owkin has a catalog of 30 live models as well as 40 additional models in the pipeline. All models are built using public and Owkin Loop data. These models are available to medical researchers via Owkin Studio and to our pharma partners through Owkin Solutions. These models differ from traditional black-box models as they are built using interpretable AI, which enables us to go further in the research and identify biomarkers responsible for the predictions. The discovery of new multimodal biomarkers is essential to identify new biological targets, optimize clinical trial design using patients subgroups, and identify patients eligible for specific treatments.

Our catalog consists of three types of models: Data Enrichment, Outcome Prediction, and Patient Identification.

Owkin has developped a strong expertise in Hepatocellular Carcinoma (HCC), the most common form of primary liver cancer, and the fourth cause of cancer-related death worldwide. Discover how we work, and how we address HCC drug development with machine learning models, specifically built for increasing clinical trial efficiency.